Hepatitis A virus (HAV) infection that is transmitted
|
|
- Claire Powell
- 5 years ago
- Views:
Transcription
1 Comparative Effectiveness of Two Doses Versus Three Doses of Hepatitis A Vaccine in Human Immunodeficiency Virus Infected and -Uninfected Men Who Have Sex With Men Yu-Tzu Tseng, 1 Sui-Yuan Chang, 2,3 Wen-Chun Liu, 4 Hsin-Yun Sun, 4 Cheng-Hsin Wu, 4 Pei-Ying Wu, 4 Ching-Lan Lu, 5 Chien-Ching Hung, 4 and Shan-Chwen Chang 4 The purpose of this prospective cohort study was to compare the serologic response between human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) receiving two and three doses of hepatitis A virus (HAV) vaccine and HIV-uninfected MSM receiving two doses of HAV vaccine. Between June 2009 and December 2010, 582 MSM aged 18 to 40 years who were seronegative for HAV were enrolled in the study. HIV-infected MSM received either two doses of HAV vaccine (1,440 enzyme-linked immunosorbent assay units) (n 5 140) with the second dose given at week 24 or three doses (n 5 225) with the second and third dose given at weeks 4 and 24, respectively, while HIVuninfected MSM (n 5 217) received two doses. The primary endpoint was seroconversion at week 48. The geometric mean concentration (GMC) of anti-hav antibody was determined at weeks 48 and 72. At week 48, the seroconversion rate was 75.7%, 77.8%, and 88.5% in intention-to-treat analysis for two-dose HIV-infected, three-dose HIV-infected, and two-dose HIV-uninfected MSM, respectively. The GMC of anti-hav antibody at week 48 for three-dose HIV-infected MSM ( log 10 miu/ml) was significantly higher than that for two-dose HIV-infected MSM ( ; P < 0.01), but was lower than HIV-uninfected MSM ( ; P < 0.01). Multivariate analysis revealed higher CD4 counts (adjusted odds ratio [AOR] for per 50 cells/ll increase, 1.13; 95% confidence interval [CI], ) and undetectable plasma HIV RNA load (AOR, 1.90; 95% CI, ) before HAV vaccination were predictive of seroconversion in HIV-infected patients. Conclusion: Serologic response rate to three and two doses of HAV vaccine was similar in HIV-infected MSM, which was lower than that in HIV-uninfected MSM receiving two doses. HAV vaccination in HIV-infected patients with a higher CD4 count and suppression of HIV replication increased the seroconversion rate. (HEPATOLOGY 2013;57: ) Hepatitis A virus (HAV) infection that is transmitted via a fecal-oral route occurs worldwide, especially in countries where sanitary and hygienic conditions are not maintained appropriately. In countries with improved sanitation and access to HAV vaccination, the incidence of HAV infection has declined significantly. The annual incidence of HAV infection has decreased from 12 per 100,000 population in 1995 to 0.6 per 100,000 population in 2009 in the United State after HAV vaccine was licensed in In Finland, the incidence of HAV infections ranged from 0.3 to 3.6 per 100,000 between Abbreviations: AOR, adjusted odds ratio; cart, combination antiretroviral therapy; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; GMC, geometric mean concentration; HAV, hepatitis A virus; HBsAg, HBV surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ITT, intention-to-treat; MSM, men who have sex with men; PP, per-protocol. From the Departments of 1 Traumatology, 2 Laboratory Medicine, and 4 Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; the 3 Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan; and the 5 Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan. Received June 7, 2012; accepted December 9, Supported by the Taiwan Centers for Disease Control (grants AIDS and EU099059). Preliminary analyses of these data were presented as Abstract O-556 at the 21st European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom, March 31-April 3,
2 HEPATOLOGY, Vol. 57, No. 5, 2013 TSENG ET AL and 2007, and most of the cases seemed to be travel-related. 2 Most HAV infections are self-limited; however, severe symptoms and complications associated with acute hepatitis A increase with age. 3,4 In addition, persons with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who develop superinfection with HAV are at increased risk for fulminant hepatitis and associated mortality. 5,6 In human immunodeficiency virus (HIV)-infected patients who acquire HAV, the duration of HAV viremia would be longer compared with that of healthy persons, 7 which may increase the risk of transmission to others. Therefore, HAV vaccination is recommended for HIV-infected patients, injecting drug users, men who have sex with men (MSM), hemophiliacs, patients with chronic liver disease (e.g., chronic HBV or chronic HCV infection), and persons planning to travel to or reside in endemic areas for HAV transmission. 8 The response rate of HAV vaccination is almost 100% among HIV-uninfected persons who receive two standard doses of HAV vaccine. 9,10 However, the immunogenicity to HAV vaccination is impaired in HIVinfected patients, and the seroconversion rate is estimated to be 68% to 88.2% after two doses of HAV vaccine (each dose containing 720 or 1,440 enzymelinked immunosorbent assay [ELISA] units) and 76% to 90% after three doses of HAV vaccine (each containing 720 ELISA units) Furthermore, the antibody titers of HIV-infected patients following HAV vaccination ( miu/ml) are significantly lower compared with those of HIV-uninfected persons (>1,000 miu/ml). 9,10 In a recently published randomized clinical trial in HIV-infected patients, the three-dose schedule of HAV vaccination (each dose containing 1,440 ELISA units) tended to achieve a higher seroconversion rate than the two-dose schedule at week 72 (78.3% versus 61.2%; P ¼ 0.07) and produce higher and more durable antibody titers after follow-up for 18 months. 15 In this study, we compared the immunogenicity of two different doses of HAV vaccination (two doses versus three doses) in HIV-infected patients and evaluated whether an additional dose of HAV vaccination in HIV-infected patients could achieve a comparable serologic response to HIV-uninfected subjects. Subjects and Methods Setting and Study Population. This prospective cohort study was conducted at a university hospital that is a major hospital designated for HIV care and provision of voluntary counseling and testing for HIV and sexually transmitted infections in Taiwan, where the overall seroprevalence of HAV in HIV-infected MSM was 50.5%, which rapidly increased in persons aged 30 to 40 years, suggesting an opportunity for HAV vaccination in persons younger than 40 years. 16,17 Subjects with and without HIV infection who were seronegative for HAV and aged 18 to 40 years were enrolled from June 25, 2009, to December 31, HIV-infected MSM were recruited from the outpatient clinics, while HIV-uninfected MSM were recruited from voluntary counseling and testing services. Exclusion criteria included failure to provide informed consent, active infection, malignancy, splenectomy, and concurrent use of systemic corticosteroids, chemotherapy, immunoglobulin, or immunomodulation agents. In Taiwan, HIV-infected patients are provided free access to HIV care that includes monitoring of CD4 count and plasma HIV RNA load, and combination antiretroviral therapy (cart) that was introduced in Taiwan in CART was defined as the use of at least three agents from at least two classes of antiretroviral agents according to the local treatment guidelines for adults with HIV infection. The study was approved by the Research Ethics Committee of the hospital and subjects gave written informed consent (NCT registration no ). HAV Vaccination Schedule. HIV-infected subjects were sequentially enrolled to receive two doses and three doses of HAV vaccine (1440 ELISA units) (HAVRIX 1440; GlaxoSmithKline, Biologicals, Rixensart, Belgium). Enrollment of HIV-infected subjects to receive three doses of HAV vaccine began after completion of enrollment of HIV-infected subjects to receive two doses of vaccine. In the two-dose vaccination schedule in HIV-infected and HIV-uninfected subjects, HAV vaccine was administered at week 0 and week 24, while in the three-dose schedule, HAV vaccine was administered at week 0, week 4, and week 24. The subjects were contacted by cell phone to Address reprint requests to: Chien-Ching Hung, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan. hcc0401@ntu.edu.tw; fax: (886) Copyright VC 2012 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI /hep Potential conflict of interest: Nothing to report.
3 1736 TSENG ET AL. HEPATOLOGY, May 2013 Table 1. Baseline Characteristics of Subjects Who Received Two or Three Doses of HAV Vaccine Characteristic Two-Dose HIV-infected Group (n ¼ 140) Three-Dose HIV-infected Group (n ¼ 225) Two-Dose HIV-Uninfected Group (n ¼ 217) P Age, years, mean (SD) 31.0 (5.3) 29.8 (5.0) 26.4 (4.8)*, ** , n (%) 2 (1.4) 4 (1.8) 13 (6) 21-30, n (%) 64 (45.7) 121 (53.8) 161 (74.2) 31-40, n (%) 74 (52.9) 100 (44.4) 43 (19.8) HBsAg-positive, n (%) 19/139 (13.7) 31/220 (14.1) 14 (6.5)*, ** >0.99 Anti-HCV positive, n (%) 8/140 (5.7) 12/223 (5.4) 2/212 (0.9)*, ** >0.99 Baseline CD4 count, cells/ll, mean (SD) 538 (227.9) 452 (199.5) <0.01 <200, n (%) 4/139 (2.9) 22/225 (9.8) , n (%) 25/139 (18) 53/225 (23.6) >350, n (%) 110/139 (79.1) 150/225 (66.7) Baseline PVL, log 10 copies/ml, mean (SD) 2.5 (1.2) 3.0 (1.4) < copies/ml, n (%) 72 (51.4) 89 (39.6) 0.03 >5 log 10 copies/ml, n (%) 2 (1.4) 17 (7.6) 0.01 cart at vaccination, n (%) 94 (67.1) 131 (58.2) 0.12 cart during the study period, n (%) 110 (78.6) 166 (73.8) 0.30 CD4 count at week 48, cells/ll, mean (SD) 605 (720.1) 506 (210.0) 0.07 PVL at week 48, log 10 copies/ml, mean (SD) 2.3 (1.2) 2.4 (1.2) copies/ml, n (%) 94 (67.1) 130 (57.8) 0.04 Abbreviation: PVL, plasma HIV RNA load. *P < 0.05 between the three-dose HIV-infected group versus the HIV-uninfected group; **P < 0.05 between the two-dose HIV-infected group versus the HIVuninfected group (two-tailed chi-square and exact measures of association between two-dose and three-dose HIV-infected groups). inquire reactions following vaccination. Anti-HAV antibody was determined at week 24 (before the last dose was administered) and week 48. The primary endpoint was seroconversion at week 48. The secondary endpoints were seroconversion at week 24 and the geometric mean concentration (GMC) of anti-hav antibody at weeks 48 and 72. Patients who had no serum available for determination of anti-hav antibody at week 24 were considered as nonresponders. At week 48, those patients who had no serum samples available, but had achieved seroconversion at week 24, were considered as responders; those without seroconversion at week 48, or having no serologic data available before the last dose of vaccination at week 24 were considered as nonresponders (intention-to-treat [ITT] analysis using last-observation-carried-forward principle). Sensitivity analyses were performed in patients who had available results of anti-hav antibody at different time points (per-protocol [PP] analysis). Matched Case-Control Study. Because the baseline characteristics were statistically significantly different in age and immunologic and virologic characteristics between the two-dose HIV-infected and three-dose HIV-infected group (Table 1), pairs from the two groups were selected that were matched for CD4 count (620 cells/ll) and age (62 years) to better assess the serologic responses to HAV vaccination between the two groups receiving different doses of HAV vaccine. Laboratory Tests. Serum samples were collected before vaccination (week 0) and at weeks 24, 48, and 72. The determinations of anti-hav antibody of serum samples were performed at the central laboratory of the hospital via chemiluminescence immunoassay according to the manufacturer s protocol (ARCHI- TECT HAVAb-IgG, Abbott Diagnostics, Wiesbaden, Germany). The laboratory staff was unaware of the HIV serostatus and the doses of HAV vaccine the subjects had received. The anti-hav antibody titers were determined using a commercially available enzymelinked immunosorbent assay (ELISA) method (ETI- AB-HAVK PLUS; DiaSorin, Saluggia, Italy). Seropositivity was defined as an anti-hav antibody titer >20 miu/ml. Plasma HIV RNA load was quantified using the Cobas Amplicor HIV-1 Monitor test (Cobas Amplicor version 1.5, Roche Diagnostics, Indianapolis, IN) with a lower detection limit of 40 copies/ml. CD4 lymphocyte count was determined using the FACFlow system (BD FACSCalibur, Becton Dickinson, San Jose, CA). Statistical Analysis. All statistical analyses were performed using SPSS version 17.0 (SPSS, Chicago, IL). Categorical variables were compared using a Fisher s exact test or chi-square test. Noncategorical variables were compared using a Mann-Whitney U test. Factors with P value 0.2, or with biological significance were included for multivariate analysis. Logistic regression analysis was used to determine the factors associated with HAV seroconversion. All comparisons were two-
4 HEPATOLOGY, Vol. 57, No. 5, 2013 TSENG ET AL Fig. 1. Study flow of HAV vaccination in HIV-infected and -uninfected MSM. tailed and a P value <0.05 was considered significant. In HIV-infected subjects, the noninferiority in terms of seroconversion rate following two-dose HAV vaccination to three-dose vaccination would be concluded if the lower boundary of the two-sided 95% confidence interval (CI) (one-sided a ¼ 0.025) for the difference in the seroconversion rate between the two groups was at least 0.1 (i.e., the noninferiority margin was set to 10%). Results During the 18-month study period, 582 subjects were enrolled: 140 HIV-infected MSM received two doses of HAV vaccine; 225 HIV-infected MSM received three doses; and 217 HIV-uninfected MSM received two doses (Fig. 1). In total, 43 (7.4%) subjects did not receive the last dose of HAV vaccine: eight (5.7%) in the two-dose HIV-infected group; 12 (5.3 %) in the three-dose HIV-infected group; and 23 (10.6%) in the two-dose HIV-uninfected group. The baseline characteristics of the subjects are shown in Table 1. HIV-uninfected subjects who were enrolled from voluntary counseling and testing services were significantly younger than HIV-infected subjects (Table 1). In HIV-infected subjects, the three-dose group was younger than the two-dose group. The seroprevalences of HBV (HBV surface antigen [HBsAg]-positive) and HCV (anti-hcv antibody positive) were similar between the two-dose and three-dose HIV-infected groups (HBV, 13.7% versus 14.1%; HCV, 5.7% versus 5.4%; P > 0.99); both the HBV and HCV seroprevalences were significantly higher than those of the HIV-uninfected group (HBV seroprevalence, 6.5%; HCV seroprevalence, 0.9%). The mean baseline CD4 count was lower (452 versus 538 cells/ll), while the baseline plasma HIV RNA load was higher (3.0 versus 2.5 log 10 copies/ml) in the three-dose HIV-infected group compared with that of the two-dose HIVinfected group (both comparisons, P < 0.01). The proportion of subjects receiving cart before HAV vaccination in three-dose group and two-dose group was 58.2% and 67.1%, respectively (P ¼ 0.12); that of the HIV-infected patients starting cart after vaccination in three-dose group and two-dose group was 15.6% and 11.4%, respectively (P ¼ 0.27). At week 24, before the last dose of HAV vaccine was administered, the seroconversion rate was 37.4% for the two-dose HIV-infected group, 62.2% for the three-dose HIV-infected group, and 52.6% for the HIV-uninfected group (P < 0.05) (Fig. 2). At week 48, the seroconversion rates were statistically significantly lower in the HIV-infected groups compared with the HIV-uninfected group in ITT analysis (twodose HIV-infected group, 75.7%; three-dose HIVinfected group, 77.8%; HIV-uninfected group, 88.5%). In PP analysis, the seroconversion rates for the three groups were 81.7% (two-dose HIV-infected group), 81.8% (three-dose HIV-infected group), and 97.9% (HIV-uninfected group). The seroconversion rate for the two-dose HIV-infected group was not inferior to that of the three-dose HIV-infected group, with a difference of 0.02 (95% CI, to 0.110) between the two groups in the ITT population and (95% CI, to 0.086) in the PP population. In the multivariate analysis of all three groups after adjustment for doses of HAV vaccination, age, positive HBsAg, and positive anti-hcv antibody, HIV-infected subjects had a statistically significantly lower seroconversion rate than HIV-uninfected subjects, with an adjusted odds ratio (AOR) of 0.46 (95% CI, ) (Table 2). In multivariate analysis among HIV-infected subjects after adjustment for age, baseline CD4 count, HIV RNA load, doses of HAV vaccine, positive HBsAg, and positive anti-hcv antibody, factors that were independently associated with seroconversion were higher CD4 counts (AOR for per 50 cells/ll increase, 1.13; 95% CI, ) and undetectable plasma HIV RNA load (<40 copies/ml) (AOR, 1.90; 95% CI, ) before vaccination (Table 2). The seroconversion rate did not differ significantly between HIV-infected subjects with and those without HBV or HCV infection. In the three-dose HIVinfected group, the seroconversion rates were 71.0% (22/31) and 79.4% (150/189) for subjects with
5 1738 TSENG ET AL. HEPATOLOGY, May 2013 Fig. 2. Seroconversion rates observed at different time points in subjects receiving two or three doses of HAV vaccine (ITT analysis). positive HBsAg and those with negative HBsAg, respectively (P ¼ 0.35), and were 66.7% (8/12) and 78.7% (166/211) for subjects with positive anti-hcv antibody and those with negative anti-hcv antibody, respectively (P ¼ 0.47). In the two-dose group, the seroconversion rate was 78.9% (15/19) and 75.8% (91/120) for subjects with positive HBsAg and those with negative HBsAg, respectively (P ¼ 0.79); 62.5% (5/8) and 76.5% (101/132) for subjects with positive anti-hcv antibody and those with negative anti-hcv antibody, respectively (P ¼ 0.40). In the matched study, 114 pairs of HIV-infected subjects who received either two doses or three doses of HAV vaccine were identified; their clinical characteristics are shown in Table 3. The seroconversion rates at week 48 were 78.1% and 84.2% for the two-dose HIV-infected group and three-dose HIV-infected group, respectively, in ITT analysis (P ¼ 0.23), with a difference of 0.06 (95% CI, to 0.163). In PP analysis, the seroconversion rates were 81.6% and 91.7% for the two-dose HIV-infected group and three-dose HIV-infected group, respectively (P ¼ 0.04). Therefore, one additional dose of hepatitis A vaccination in HIV-infected patients was associated with a statistically significantly higher seroconversion rate in PP analysis (AOR, 2.50; 95% CI, ), but not in ITT analysis (AOR, 1.44; 95% CI, ) (Table 4). Compared with the two-dose HIV-infected group, the GMC of anti-hav antibody was statistically significantly higher for the three-dose HIV-infected group (week 48, versus log 10 miu/ml, P < 0.01; week 72, versus log 10 miu/ml, P<0.01) (Fig. 3). The proportion of HAV antibody titer that was >20 miu/ ml at weeks 48 and 72 was 88.6% (109/123) and 86.6% (110/127), respectively, for the two-dose HIVinfected group and 89.2% (182/204) and 86.9% (173/199), respectively, for the three-dose HIVinfected group (data not shown). The GMC in the three-dose HIV-infected group was significantly lower than that of the two-dose HIVuninfected group (week 48, versus log 10 miu/ml, P < 0.01; week 72, versus log 10 miu/ml, P ¼ 0.02) (Fig. 3). The proportion of HAV antibody titer that was >20 miu/ml at weeks 48 and 72 for HIV-uninfected group was 100% (172/172) and 100% (147/ 147), respectively. HAV vaccination did not cause intolerable adverse effects in either group of subjects, with the most adverse effect being mild tenderness at the local injection site in 24 hours of vaccination that was reported in 51.6% of all subjects (HIV-infected versus HIVuninfected, 51.7% versus 51.6%, P ¼ 0.98) (data not shown). Table 2. Multivariate Analysis of Factors Associated With Seroconversion After HAV Vaccination in HIV-Infected and -Uninfected MSM Factor AOR (95% CI) P HIV-infected and HIV-uninfected* Age, per 1-year increase 1.00 ( ) 0.91 HIV-infected versus HIV-uninfected 0.46 ( ) <0.01 Three-dose versus two-dose HAV vaccination 1.12 ( ) 0.67 HIV-infected CD4 count (per 50 cells/ll increase) 1.13 ( ) <0.01 PVL 40 versus PVL >40 copies/ml 1.90 ( ) 0.02 Anti-HCV positive versus anti-hcv negative 0.45 ( ) 0.12 HBsAg-positive versus HBsAg-negative 0.62 ( ) 0.21 Three-dose versus two-dose HAV vaccination 1.47 ( ) 0.16 Fig. 3. GMC (log 10 miu/ml) of anti-hav antibody in the three groups of subjects at weeks 48 and 72. Abbreviation: PVL, plasma HIV RNA load. *Multivariate analysis after adjustment for doses of HAV vaccination, age, positive HBsAg, and positive anti-hcv antibody. Multivariate analysis after adjustment for age, baseline CD4 count, HIV RNA load, dose of HAV vaccine, HBsAg positivity, and anti-hcv antibody positivity.
6 HEPATOLOGY, Vol. 57, No. 5, 2013 TSENG ET AL Table 3. Clinical Characteristics of 114 Matched Pairs of HIV-Infected Subjects Who Received Two Doses and Three Doses of HAV Vaccine Characteristic Two-Dose Group (n ¼ 114) Three-Dose Group (n ¼ 114) P Age, years, mean (SD) 31.0 (4.96) 30.3 (4.73) , n (%) 1 (0.9) 1 (0.9) 21-30, n (%) 52 (45.6) 57 (50.0) 31-40, n (%) 61 (53.5) 56 (49.1) HBsAg-positive, n (%) 17 (14.9) 22/111 (19.8) 0.38 Anti-HCV positive, n (%) 6 (5.3) 10/111 (9.0) 0.31 Baseline CD4 count, cells/ll, mean (SD) 500 (173) 501 (176) 0.97 <200, n (%) 3 (2.6) 2 (1.8) , n (%) 20 (17.5) 21 (18.4) >350, n (%) 91 (79.8) 91 (79.8) Baseline PVL, mean (SD) log 10 copies/ml 2.6 (1.24) 2.7 (1.30) 0.35 PVL 40 copies/ml, n (%) 58/113 (51.3) 58/111 (52.3) 0.9 PVL >5 log 10 copies/ml, n (%) 2/113 (1.8) 0 (0) 0.5 Cart at vaccination, n (%) 76 (66.6) 72 (63.2) 0.68 CD4 at week 48, cells/ll, mean (SD) 518 (183) 536 (207) 0.53 PVL at week 48, log 10 copies/ml, mean (SD) 2.4 (1.22) 2.4 (1.12) 0.58 PVL at week 48, 40 copies/ml, n (%) 59/96 (61.5) 55/95 (57.9) 0.62 Seroconversion at week 24, n (%) 42/108 (38.9) 71/105 (67.6) <0.01 Seroconversion at week 48, n (%) ITT analysis 89 (78.1) 96 (84.2) 0.23 PP analysis 84/103 (81.6) 88/96 (91.7) 0.04 Abbreviation: PVL, plasma HIV RNA load. Discussion In this prospective cohort study of HAV vaccination in HIV-infected and HIV-uninfected MSM, we found that an additional dose of HAV vaccination in HIVinfected patients failed to achieve a comparable serologic response rate to HIV-uninfected persons. While the three-dose HAV vaccination schedule achieved a higher serologic response rate than the two-dose HAV vaccination schedule in PP analysis in HIV-infected matched pairs, the difference was not statistically significant in ITT analysis. The strength of our study is that we enrolled a large number of subjects consisting of HIV-infected as well as HIV-uninfected subjects to evaluate the serologic responses to two different doses of HAV vaccination. Furthermore, the completion rates of follow-up for seroconversion and antibody titers were high at weeks Table 4. Factors Associated With Seroconversion in ITT Analysis Using the Last Observation Carried Forward Principle, and PP Analysis in the 114 Matched Pairs of HIV-Infected Patients Factor AOR (95% CI) P ITT analysis Three-dose versus two-dose vaccination 1.44 ( ) 0.29 CD4 count (per 50 cells/ll increase) 1.09 ( ) 0.11 PP analysis Three-dose versus two-dose vaccination 2.50 ( ) 0.04 CD4 count (per 50 cells/ll increase) 1.16 ( ) and 72. Several limitations need to be acknowledged, however. This study was not a randomized clinical trial, and the HIV-infected subjects who were enrolled to receive three doses of HAV vaccine and those who received two doses of HAV vaccine differed in several important clinical characteristics. Although we selected subjects in the two groups that were comparable in terms of age, CD4, and plasma HIV RNA load for comparisons of serologic responses, we were only able to demonstrate the superiority of a three-dose HAV vaccination schedule to a two-dose schedule in PP analysis instead of ITT analysis. The seroconversion rate of HAV vaccination in HIV-infected patients has been shown to be lower than that in HIV-uninfected persons before the cart era. 9,10 A prospective study conducted in Australia during , which recruited 90 HIV-infected and 46 HIV-uninfected MSM to receive two doses of HAV vaccine (720 ELISA units), showed that the seroconversion rate in HIV-infected persons (88.2%) was lower than that in HIV-uninfected persons (100%) (P ¼ 0.03). 9 In the era of cart, adding a third dose to the standard two-dose HAV vaccination schedule has been tried to enhance immunogenicity in HIVinfected patients. In a clinical trial by Launay et al. 15 in which 95 HIV-infected patients were randomized to receive three doses (n ¼ 46) or two doses (n ¼ 49) of HAV vaccine (1,440 ELISA units), the seroconversion rates were 82.6% and 69.4% for the three-dose group and two-dose group, respectively, at week 28 (primary
7 1740 TSENG ET AL. HEPATOLOGY, May 2013 endpoint; P ¼ 0.13, ITT analysis) and 78.3% and 61.2%, respectively, at week 72 (P ¼ 0.07). In our study, the subjects were all younger MSM with significantly higher CD4 counts than those in the study by Launay et al., and more than 60% of our HIVinfected subjects were receiving cart; regardless, three doses of HAV vaccination in our HIV-infected MSM failed to achieve a seroconversion rate or GMC comparable to that of HIV-uninfected MSM who received two doses of HAV vaccination at weeks 48 and 72, both in ITT and PP analyses. In this study, we identified that a higher CD4 count and undetectable plasma HIV RNA load were predictive of serologic responses in HIV-infected adult patients (Table 2), which was similar to the findings of the retrospective study by Overton et al. 19 that enrolled 268 HIV-infected patients who had received at least one dose of HAV vaccine (Havrix, 1,440 ELISA units) and to those of the prospective study by Weinberg et al. 14 that enrolled 152 HIV-infected patients aged 2 to 21 years. In a subgroup analysis of our study, we found that for patients with a plasma HIV viral load of 40 copies/ml and a CD4 count of 200 cells/ll at baseline, the seroconversion rates were 81.2% (56/69) and 89.0% (73/82) in the twodose group and three-dose group, respectively, compared with 88.5% (192/217) in the HIV-uninfected group in ITT analysis (P > 0.05 in two comparisons). The response rate could be further increased to 92.1% (58/63) in the three-dose group who had a CD4 count of 350 cells/ll and an HIV viral load of 40 copies/ml (data not shown). The findings of our subgroup analysis suggest that, to improve immunogenicity, HAV vaccination should be recommended for HIV-infected patients who have achieved good virologic and immunologic responses to cart. Although more studies are warranted to confirm our findings, we suggest that three doses of HAV vaccine could maximize the response rate in HIV-infected patients who have a CD4 count of 350 cells/ll. HIV-infected adult patients who received two doses of HAV vaccine have been demonstrated to generate a lower anti-hav antibody titer that was less durable compared with HIV-uninfected persons and higher GMCs over time among HIV-infected adults were associated with lower plasma HIV RNA loads. 20 In our study, we also found that, despite an additional dose, the GMC for three-dose HIV-infected MSM remained lower than that for two-dose HIV-uninfected MSM at week 48 ( versus log 10 miu/ml, P < 0.01) and at week 72 ( versus log 10 miu/ml, P ¼ 0.02). Whether further increase of doses and dosing frequency of HAV vaccine among HIV-infected patients, similar to those demonstrated in a recent HBV vaccination study by Launay et al., 21 can improve the efficacy warrants more studies. While our study and the aforementioned study by Launay et al. 15 failed to demonstrate a statistically significantly higher seroconversion rate in HIV-infected patients who received three doses of HAV vaccination than those who received two doses, an additional dose of HAV vaccine did significantly increase the anti-hav antibody titers (Fig. 3). 15 Of those initial responders, Launay et al. found that 85% could maintain a protective antibody titer for a follow-up duration of 3.7 years. 22 In conclusion, the serologic response rate to three and two doses of HAV vaccine was similar in HIV-infected MSM, which was lower than that in HIV-uninfected MSM who received two doses. Administration of HAV vaccine in HIV-infected patients with higher CD4 counts (preferably >200 cells/ll) and suppression of HIV replication increased the seroconversion rate. Acknowledgment: We thank the subjects who participated in the study and Chin-Fu Hsiao (Division of Biostatistics and Bioinformatics, National Health Research Institutes, Taiwan) for statistical analyses. References 1. Centers for Disease Control and Prevention. Hepatitis A information for health professionals. htm, Accessed on 30 November, Broman M, Jokinen S, Kuusi M, Lappalainen M, Roivainen M, Liitsola K, et al. Epidemiology of hepatitis A in Finland in J Med Virol 2010;82: Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B.Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998;128: Brown GR, Persley K.Hepatitis A epidemic in the elderly. South Med J 2002;95: Keeffe EB.Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver disease?. Am J Gastroenterol 1995;90: Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338: Ida S, Tachikawa N, Nakajima A, Daikoku M, Yano M, Kikuchi Y, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002;34: Advisory Committee on Immunization Practice.Recommended adult immunization schedule: United States, Ann Intern Med 2012; 156: Neilsen GA, Bodsworth NJ, Watts N.Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997;176: Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003;187:
8 HEPATOLOGY, Vol. 57, No. 5, 2013 TSENG ET AL Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, Kessler H, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000;14: Hess G, Clemens R, Bienzle U, Sch onfeld C, Schunck B, Bock HL.Immunogenicity and safety of an inactivated hepatitis A vaccine in anti- HIV positive and negative homosexual men. J Med Virol 1995;46: Tilzey AJ, Palmer SJ, Harrington C, O Doherty MJ.Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996;14: Weinberg A, Gona P, Nachman SA, Defechereux P, Yogev R, Hughes W, et al. Antibody responses to hepatitis A virus vaccine in HIVinfected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006;193: Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC Study. J Acquir Immune Defic Syndr 2008;49: Sun HY, Kung HC, Ho YC, Chien YF, Chen MY, Sheng WH, et al. Seroprevalence of hepatitis A virus infection in persons with HIV infection in Taiwan: implications for hepatitis A vaccination. Int J Infect Dis 2009;13:e199-e Tseng YT, Sun HY, Chang SY, Wu CH, Liu WC, Wu PY, et al. Seroprevalence of hepatitis virus infection in men who have sex with men aged years in Taiwan. J Formos Med Assoc 2012;101: Santagostino E, Gringeri A, Rocino A, Zanetti A, de Biasi R, Mannucci PM.Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-hiv positive and negative hemophilic patients. Thromb Haemost 1994;72: Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG.Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007;14: Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, et al. Long-term durability of immune response after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011;203: Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011;305: Kerneis S, Desaint C, Brichler S, Rey D, Belarbi L, Gordien E, et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr 2011;57: e63-e66.
Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Wang-Huei Sheng, 1,3,6,a Jia-Horng Kao, 5,a Pei-Jer Chen, 5 Li-Ming
More informationHepatitis A virus (HAV) is transmitted
HEPATOLOGY, VOL. 68, NO. 1, 2018 AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES VIRAL HEPATITIS Serologic Responses and Effectiveness of Hepatitis A Vaccination Among Human Immunodeficiency Virus
More informationFor the additional vaccination phase
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEpidemiology of hepatitis E infection in Hong Kong
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epidemiology of hepatitis E infection in Hong Kong DPC Chan *, KCK Lee, SS Lee K e y M e s s a g e s 1. The overall anti hepatitis E virus (HEV) seropositivity
More informationHepatitis A Universal Vaccination of Military Personnel: The Russian Experience
Hepatitis A Universal Vaccination of Military Personnel: The Russian Experience V. Akimkin 1, Y. Sabanin 2, V. Rihter 2, V. Shumilov 3, V. Shevtsov 3, P. Ogarkov 4, S. Romanchuk 5, A. Rasuli 6 1 Burdenko
More informationSeroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
IJPM Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province Parisa Shoaei 1, Laleh Zeidabadinejad 1, Razieh Hassannejad 1, Behrooz Ataei 1, Majid Yaran 1, Nazila Kassaian
More informationsubjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis B virus (HBV) infection is an important. Brief Communication
Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,
More informationMolecular Epidemiology of Hepatitis D Virus Infection among Injecting Drug Users with and without Human Immunodeficiency Virus Infection in Taiwan
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2011, p. 1083 1089 Vol. 49, No. 3 0095-1137/11/$12.00 doi:10.1128/jcm.01154-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Molecular Epidemiology
More informationINTRODUCTION. Jong Hun Kim*, George Psevdos Jr,, Vanessa Groce, and Victoria Sharp
Gut and Liver, Vol. 6, No. 1, January 2012, pp. 86-91 ORiginal Article Persistence of Protective Hepatitis B Surface Antibody Titers after Successful Double-Dose Hepatitis B Virus Rescue Vaccination in
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationLong-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSelected Primary-Care Issues in HIV Disease
Perspective Selected Primary-Care Issues in HIV Disease Primary care for HIV-infected patients includes ensuring that eligible patients receive hepatitis B and A virus vaccinations, all women undergo appropriate
More informationEstimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants
ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationUniversal hepatitis B (HB) immunization has
Determination of Immune Memory to Hepatitis B Vaccination Through Early Booster Response in College Students Chyi-Feng Jan, 1,2 Kuo-Chin Huang, 1 Yin-Chu Chien, 3 Donald E. Greydanus, 2 H. Dele Davies,
More informationSynopsis for study HAV-112 EXT M210 (110678)
Synopsis for study HAV-112 EXT M210 (110678) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationVaccination of patients with chronic viral hepatitis against Hepatitis A and Hepatitis B
Vaccination of patients with chronic viral hepatitis against Hepatitis A and Hepatitis B Professor Sergey L. Mukomolov Saint-Petersburg Pasteur Institute WHITE NIGHTS OF HEPATOLOGY 2013 6-7 June Saint-Peterburg
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before approval of AMBIRIX. This scientific discussion has
More informationDidactic Series. Immunizations in HIV Infected Individuals. Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017
Didactic Series Immunizations in HIV Infected Individuals Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017 Slides author: Ankita Kadakia, MD, AAHIVS 1 Learning Objectives To learn how vaccines induce
More informationGuideline for the immunization of HIV infected persons in Sri Lanka
DOI: http://doi.org/10.4038/joshhm.v3i0.64 Guideline for the immunization of HIV infected persons in Sri Lanka Dr. M. K. Darshanie Mallikarachchi, Consultant Venereologist, Provincial General Hospital
More informationChronic hepatitis B virus (HBV) infection remains a major
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationEmerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea
J Korean Med Sci 7; 22: 218-22 ISSN 111-8934 Copyright The Korean Academy of Medical Sciences Emerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea Vaccination
More informationhepatitis B virus B 15% 25 HBsAg B HBV HBsAg 15% 20% HBV HBV 90% 16 HIV HBV
hepatitis virus HV 20 15% 25 20 30 HV HsAg 3 5 100 HV 15% 20% HV HsAg HV HV HV 90% 16 5% HV 10 59 http://www.aids-care.org.tw HV CD8 73% 98% HV 90% HV HsAg 6 10% HsAg 0.5% 1% HV HV HV HV HCV TNF- TNF-
More informationHCV HIV +*+ Human immunodeficiency virus HIV hepatitis C virus HCV HIV HCV HCV HIV HIV
,**- The Japanese Society for AIDS Research The Journal of AIDS Research +0 HIV HCV + + + + + + + + +, +, :HCV HIV HAART / : +*+ +*0,**- Human immunodeficiency virus HIV hepatitis C virus HCV HIV,* HCV
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationPrevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy
Vaccine 24 (2006) 3095 3099 Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy Sudawan Siriaksorn a, Thanyawee
More informationScreening of Hepatitis B Virus Infection among HIV- Infected Patients Receiving Antiretroviral Therapy
Original Article Vol. 27 No. 2 Screening of hepatitis B virus infection:- Chotiprasitsakul D, et al. 69 Screening of Hepatitis B Virus Infection among HIV- Infected Patients Receiving Antiretroviral Therapy
More informationPrimary Human Immunodeficiency Virus Infection Presenting as Elevated Aminotransferases
Also available online http://www.e-jmii.com ISSN 1684-1182 Volume 43 Number 3 June 2010 Indexed in MEDLINE/Medicus, SCIE, BIOSIS, EMBASE, Aidsline, CancerLit, Chemical Abstracts, HealthSTAR The official
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationVOICES OF THE HIDDEN
VOICES OF THE HIDDEN I M P L E M E N TAT I O N O F T H E P E O P L E L I V I N G W I T H H I V S T I G M A I N D E X I N TA I WA N Yi-Chi Chiu 1, 2, Ting-Shu Wu 1, Yuan-Ti Lee 3, 4, Ning-Chi Wang 5, Wing-Wai
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationAre booster immunisations needed for lifelong hepatitis B immunity?
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationResponse to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Response to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy Linda Aurpibul, 1 Thanyawee Puthanakit,
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationChronic infection with hepatitis B virus (HBV) is still a
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:527 534 Incidence and Determinants of Spontaneous Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B HWAI I YANG,*,, HSIU LIAN HUNG, MEI
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical presentations and virologic characteristics of primary human immunodeficiency virus type-1 infection in a university hospital in Taiwan
J Microbiol Immunol Infect 2004;37:271-275 Clinical presentations and virologic characteristics of primary human immunodeficiency virus type-1 infection in a university hospital in Taiwan Hsin-Yun Sun
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationA scoring system for the effectiveness of Hepatitis-B vaccination in children receiving treatment for cancer
Turkish Journal of Cancer Vol.3/ No. 4/2 A scoring system for the effectiveness of Hepatitis-B vaccination in children receiving treatment for cancer FUNDA ÇORAPÇIOĞLU, FAİK SARIALİOĞLU, NUR OLGUN, KAMER
More informationChanging Prevalence of Anti-Hepatitis A Virus in Adolescents in A Rural Township in Taiwan
Original Article 321 Changing Prevalence of Anti-Hepatitis A Virus in Adolescents in A Rural Township in Taiwan Jing-Yi Chen 1,2,5, MD; Jui-Chin Chiang 1,2,6, MD; Sheng-Nan Lu 2,3,4, MD, MPH, PhD; Shu-Fen
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 1.1111/j.1469-691.24.19.x Chronological evolution of,, and neutralisation antibodies after infection with SARS-associated coronavirus P.-R. Hsueh 1,2, L.-M. Huang 3, P.-J. Chen 2, C.-L.
More informationHepatitis B virus (HBV) infection is a global
VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung
More informationJournal Club 3/4/2011
Journal Club 3/4/2011 Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants JAMA. 2011 Feb 9;305(6):576-84. Jones et al Dept of Pediatrics, Imperial College,
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChronic hepatitis B (CHB) infection is a large
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationBHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHepatitis C Seroprevalence Among HIV-Infected Childbearing Women in New York State in 2006
DOI 10.1007/s10995-015-1853-4 Hepatitis C Seroprevalence Among HIV-Infected Childbearing Women in New York State in 2006 L. Ghazaryan 1 L. Smith 2 M. Parker 3 C. Flanigan 4 W. Pulver 2 T. Sullivan 5 A.
More informationcoinfected patients predicts HBsAg clearance during long term exposure to tenofovir
Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia
More informationHepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan
Original Article 137 Hepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan Chang-Jung Chang 1, MD; Jui-Chin Chiang 1,2,6, MD; Sheng-Nan
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationrisk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
More informationShould an additional dose of measles-containing vaccine be recommended for HIVinfected adolescents and adults?
Should an additional dose of measles-containing vaccine be recommended for HIVinfected adolescents and adults? Introduction At the October 2015 meeting of the Strategic Advisory Group of Experts (SAGE)
More informationJapanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy
Available online at www.sciencedirect.com Vaccine 25 (2007) 8257 8261 Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy Thanyawee
More informationIncomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees
Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Yin-Chu Chien, 1 Chyi-Feng Jan, 2 Chun-Ju Chiang, 3 Hsu-Sung
More informationResponse to hepatitis B vaccination among HIV-infected adults in Vietnam
Response to hepatitis B vaccination among HIV-infected adults in Vietnam The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation
More informationExperience of Pentavalent Human-bovine Reassortant Rotavirus Vaccine Among Healthy Infants in Taiwan
ORIGINAL ARTICLE Experience of Pentavalent Human-bovine Reassortant Rotavirus Vaccine Among Healthy Infants in Taiwan Chien-Chih Chang, 1 Mei-Hwei Chang, 1 * Tzou-Yen Lin, 2 Hong-Chang Lee, 3 Wu-Shiun
More informationChin-Hui Yang, M.D. Hui-Rong Liu, Sung-Yin Chen, Yen-Fang Huang, Shih-Yan Yang Third Division, Centers for Disease Control, Department of Health,
Comparison of ff Factors affecting the mortality rate of Injecting Drug Users with HIV infection in Taiwan Chin-Hui Yang, M.D. Hui-Rong Liu, Sung-Yin Chen, Yen-Fang Huang, Shih-Yan Yang Third Division,
More informationSynopsis of study HBV-314 BST 280 (108988)
Synopsis of study HBV-314 BST 280 (108988) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationHepatitis A Vaccination: Is It Necessary For Thai Adults?
ISPUB.COM The Internet Journal of Asthma, Allergy and Immunology Volume 3 Number 2 Hepatitis A Vaccination: Is It Necessary For Thai Adults? S Sugaroon, V Wiwanitkit Citation S Sugaroon, V Wiwanitkit.
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHuman Hepatitis B Immunoglobulin, solution for intramuscular injection.
New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF is a sterile,
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand
Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand http://waipra.blogspot.com/2011/02/9.html Burden of disease in Thailand Liver diseases
More informationViral Hepatitis. Background
Viral Hepatitis Background Hepatitis or inflammation of the liver can be caused by infectious and noninfectious problems. Infectious etiologies include viruses, bacteria, fungi and parasites. Noninfectious
More informationHEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN
UNIVERSAL HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN MEI-HWEI CHANG, M.D., CHIEN-JEN CHEN, SC.D., MEI-SHU LAI, M.D., HSU-MEI HSU, M.P.H., TZEE-CHUNG WU,
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationHepatitis B Vaccine Responsiveness and Clinical Outcomes in HIV Controllers
Hepatitis B Vaccine Responsiveness and Clinical Outcomes in HIV Controllers Jason F. Okulicz 1,2 *, Octavio Mesner 1, Anuradha Ganesan 1,3, Thomas A. O Bryan 1,2, Robert G. Deiss 1,4, Brian K. Agan 1 1
More informationEDMA HIV-AIDS TEAM Fact Sheet November 2007
EDMA HIV-AIDS TEAM Fact Sheet November 2007 1. HIV Facts AIDS epidemic update UNAIDS Epidemic Update, November 2007 (1) 760,000 people to be living with HIV in Western and Central Europe in 2007. 31,000
More informationCD4 + T. antiretroviral therapy ART CD4 + T. Kaplan-Meier
2018 12 22 12 1229 HIV /AIDS CD4 + T 1 1 1 2 1 1 1 1 1 1 1 1 1 / human immunodeficiency virus /acquired immunodeficiency syndrome HIV /AIDS antiretroviral therapy ARTCD4 + T CD4 ART HIV /AIDS ART CD4 ART
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA
PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha
More informationPrevalence and correlates of Kaposi s sarcomaassociated herpesvirus infection in a sample of men who have sex with men in eastern China
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Virology Papers Virology, Nebraska Center for 2012 Prevalence and correlates of Kaposi s sarcomaassociated herpesvirus infection
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01367.x Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationClinical Infectious Diseases Advance Access published September 9, Acute HIV infection is beneficial for controlling chronic hepatitis B
Clinical Infectious Diseases Advance Access published September 9, 2014 1 Acute HIV infection is beneficial for controlling chronic hepatitis B Yanmei Jiao *, Ning Li *, Xinyue Chen, Tong Zhang, Hongjun
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.09 A Correlative Study of Biochemical, Virological
More informationClinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?
Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationPharmacokinetic-guided Antiretroviral Therapy. Chih-Hsun Tai, M.S., RPh. Department of Pharmacy National Taiwan University Hospital
Pharmacokinetic-guided Antiretroviral Therapy Chih-Hsun Tai, M.S., RPh. Department of Pharmacy National Taiwan University Hospital Introduction HAART allows a complete viral suppression But Not all patients
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More information